Ovarian cancer patient is first to receive new therapy targeting Mage-A4 protein

Tracy Tomlinson, a 58-year-old woman living with advanced ovarian cancer, has become the first patient worldwide to receive a novel experimental therapy known as ZI-MA4-1. The treatment was administered at the Christie NHS Foundation Trust in Manchester as part of a clinical trial.

The trial aims to evaluate the drug's effectiveness across multiple cancer types, including ovarian, lung, sarcomas, and head and neck cancers. Tomlinson has been living with ovarian cancer since her diagnosis in 2020 and has previously undergone surgery and chemotherapy.

The ZI-MA4-1 therapy works by integrating two key mechanisms: it utilizes the body's natural killer (NK) cells, which are specialized immune cells designed to destroy abnormal cells, and employs engineered T-cell receptors (TCRs) to specifically recognize and target tumors that produce the Mage-A4 protein. Experts believe Mage-A4 is an ideal target for attacking cancerous cells, as it is found in several types of cancer.